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Efficient and effective protein quality control are crucial components of  cellular homeostasis in the 
presence of  misfolded and aggregated proteins. One method for identifying the mechanistic targets 
of  such protein quality control is via appropriate mouse models.  Through exogenous alterations via 
methods such as drug injection on genetically modified mice, various crucial components of  the 
protein quality control system may be identified.  Such modulation could be induced in an effort to 
increase proteasome efficiency in clearing protein aggregates and alleviate dangerous levels of  protein 
cytotoxicity.  Thus in this experiment, a drug targeting the protein quality control system was 
administered to SOD1G93A transgenic mice to observe the potential alleviation of  ALS symptoms.  
Drug efficacy was gauged based off  of  a rotarod balance test, grip strength test, and weight 
measurements.  The drug’s efficacy in vivo was the main objective of  this research project.  Additional 
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Neurodegenerative disorders, though occurring less in the general population compared to other 
maladies such as cancer, heart disease, and chronic obstructive pulmonary disease (COPD), 
nonetheless generate significant fear among the vulnerable and the afflicted alike (Kinsella 1992).  
The general cause for such distress stems from the degenerative nature of  such disorders, which not 
only induce functional loss of  motor operations, but also steadily dissolve memories and personality.  
The four major neurodegenerative disorders: Alzheimer’s, Parkinson’s, Huntington’s, and 
Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease/ALS) all result in motor and cognitive loss, 
and are all presently untreatable (Shany-Ur and Rankin 2011).  Of  these disorders, ALS has been 
clinically documented to progress the fastest, with time of  visible onset to fatality usually ranging 
from three to five years (Glicksman 2011).  It is also extremely frightening; due to progressive 
muscle paralysis, patients generally die of  suffocation as their respiratory muscles steadily shut down.  
The only FDA approved drug, riluzole, only extends patient life by one to three months (Dall’Igna, 
Bobermin et al. 2013).   
Further complicating the issue of  treatment is that the mechanistic effects and benefits of  
riluzole are poorly understood.  Most researchers and clinicians gravitate towards the claim that it 
acts in dual-function manner, both accelerating glutamate uptake and clearance at neural synapses 
and reducing levels of  neurotransmitter release as well (Blasco, Mavel et al. 2014).  It has also been 
documented to block Tetrodotoxin (TTX)-sensitive sodium channels and directly inhibit kainite and 
N-methyl -D aspartate (NMDA) receptors (Dennys, Armstrong et al. 2015).  TTX is a neurotoxin 
which binds to voltage-gated sodium channels in neuron membranes, thus preventing sodium ion 
permeability and firing of  action potentials (Bane, Lehane et al. 2014).  NMDA receptors are ion 
channels which are activated via glutamate or glycine binding, thus facilitating cation passage such as 




sodium, calcium, and potassium ions (Liu and Zhang 2000).  Frustratingly, over thirty Phase II and 
III clinical trials, many containing drugs with similar functions to riluzole have all failed to display 
significant clinical benefits (Genc and Ozdinler 2014).  Consequently, there has been a surge in 
effort to identify another mechanistic pathway for novel drugs to target.  A common target and 
purported cause of  ALS is the gain-of-function mutation in the superoxide dismutase (SOD1) gene 
and protein, which facilitates its aggregation in motor neurons (Deng, Shi et al. 2006).  The normal 
function of  SOD1 is to convert toxic and dangerous superoxide radicals into less harmful forms 
such as molecular oxygen and hydrogen peroxide (Moreira, Pereira et al. 2013).  Numerous studies 
have indicated that such aggregation can have numerous deleterious effects ranging from 
mitochondrial vacuolization to intracellular cytotoxicity by way of  clogged and dysfunctional 
proteasomes (Martins and English 2014).  It comes as no surprise that countless studies have 
struggled to alleviate ALS phenotype via extermination of  SOD1 aggregates.  One possible 
mechanistic target is the crucial p53 “guardian of  the genome” protein, which is responsible for a 
plethora of  functions, ranging from cell growth maintenance to most importantly for ALS, protein 
quality control (Periz, Lu et al. 2015).     
Given its prevalence and precedent in previous ALS research, the SODG93A mutation is one 
of  the most widely and densely studied in the field (Teuling, van Dis et al. 2008).  Although its 
occurrence in humans is much more infrequent compared to other mutations, researchers hope that 
mechanistic discoveries of  the mutation may hold significance for other mutations as well.  
However, beyond the scope of  the various SOD1 mutations ranging from A4V to G85R, numerous 
other focal points are being scrutinized, such as C9orf72 and TDP43 (Ajroud-Driss and Siddique 
2015).  Nevertheless, one of  the best models still remains the transgenic SODG93A mouse, having 
been studied in tremendous detail by countless laboratories.  It is currently a standard mouse model 
in the ALS animal research field, and will be the main method of  study for this thesis project.   




The transgenic SODG93A mouse generally possesses over 20 copies of  the mutant G93A 
transgene throughout its genome, which confers its strong ALS-related phenotype (Ohgomori, 
Yamada et al. 2016).  Regardless, the model is not perfect, with some researchers claiming that such 
strong transgene presence and upregulation could present a confounding variable in itself  (Pfohl, 
Halicek et al. 2015).  Others suggest that such high protein levels could flood and overload cells, 
thus causing ALS-like symptoms from severe protein excess or other unknown mechanisms not 
mechanistically similar to clinical ALS (Pfohl, Halicek et al. 2015).  Still, the mouse has been an 
invaluable tool in the ALS field and has helped pave the way for a multitude of  discoveries and 
advancements.   
Despite the depth of  knowledge gained from this mouse model, many questions still remain 
as to the mechanisms of  ALS progression and their fundamental cause.  A commonly held belief  is 
that ALS is caused by a toxic gain-of-function generated by the abnormal aggregation of  mutant 
SOD1 proteins (Deng, Shi et al. 2006).  Complete knockout of  the SOD1 gene has also been 
proven to not cause ALS-like symptoms.  A plethora of  evidence supports these theories (Lobsiger, 
Boillee et al. 2013).  Some labs have shown that innate structural deformities in mutant SOD such as 
G93A facilitate protein aggregation (Wright, Antonyuk et al. 2013).  Others mention the ensuing 
intracellular chaos that occurs following aggregate formation (Karch, Prudencio et al. 2009).  
Unfortunately, with the consequent concern of  what the SOD1 aggregates do to dysregulate cellular 
function and by what means, significant debate has been generated.  Research has shown that among 
other acts, aggregates can accumulate at the mitochondria, ultimately causing vacuolation of  the 
mitochondria and the release of  many cytotoxic enzymes (Higgins, Jung et al. 2003).   
Researchers have scrambled over the years to target as many mechanistic pathways and 
checkpoints as possible to halt the progression of  ALS in SODG93A mice.  Such efforts have included 
riluzole-like glutamate de-excitatory treatments, calcium regulation treatments, and modulations to 




SOD1 regulation and levels (Prell, Lautenschlager et al. 2013).  Many methods have seen 
improvement, yet fail to succeed in human trials.  Whether a better target or a drug cocktail is 
needed has yet to be determined, but regardless, the search continues for another mechanism to halt 
or prevent mutant SOD1-related ALS. 
One new focus has been to remove attention from alleviating SOD1 aggregate-related 
damages and instead concentrate on the source of  the toxicity: the protein quality control system.  
Studies have indicated that proteasome functionality in the presence of  SOD1G93a aggregates is 
diminished, which could not only allow further protein aggregate formation, but also interrupt 
numerous other intracellular regulatory processes (Kitamura, Inada et al. 2014).  As such, a logical 
step would be to target the overarching control mechanism of  cellular defense, the p53 tumor-
suppressor protein.  Some research has shown that p53 levels may already be quite high in the motor 
neurons of  ALS patients, the consequence of  cells struggling to remove the progressive buildup of  
insoluble protein aggregates (Turnquist, Horikawa et al. 2016).  It is possible that aggregates may 
clog proteasome pores, thus diminishing overall protein regulatory efficiency. The subsequent 
buildup of  aggregate concentration could have substantial and progressive deleterious effects on the 
cell, urging p53 levels high enough to induce eventual apoptosis (Kitamura, Inada et al. 2014).  
 Of  curiosity is what modulation of  the p53 level might do to affect protein quality control 
levels.  It seems that this may depend on the stage in which p53 levels are altered.  Too late in ALS 
progression and excess p53 levels could simply tip the scale towards immediate apoptosis, thus 
worsening symptoms.  If  p53 is elevated early enough in the diseases progression however, it could 
possibly confer a protective effect, allowing relatively healthy motor neurons to resist ALS 
progression to a measurable degree.  The purpose of  this thesis project is to determine if  early p53 
level increases do indeed reduce ALS phenotype progression or onset and if  so to what extent.   




Modulation will be done via intraperitoneal drug injections of  the drug Tenovin-6, which 
serves to increase p53 levels via deactivation of  a p53 gene deacetylase.  Tenovin-6 (Fig. 1B) is a 
small molecule activator of  p53 transcriptional activity and a more effective water-soluble derivative 
of  Tenovin-1 (Fig. 1A).  The drug enacts its effect via inhibition of  the Sirtuin 1, 2, and 3 protein 
deacetylases.  The main focus, sirtuin 1 (SIRT1), is an NAD+-dependent class III histone 
deacetylase, which deacetylates p53 at lysine 382 and modulates numerous other histone/non-
histone proteins as well, thus reducing p53 transcription and functionality (Sasca, Hahnel et al. 
2014).  The goal of  this mechanism (Fig. 3A) during activation is to ultimately reduce p53 levels, 
thus leading to cell survival.  One potential method of  stalling ALS symptoms may be to increase 
p53 levels via SIRT1 inhibition.  A complicating factor however would be to determine the proper 
dose of  SIRT1 inhibitor necessary to upregulate protein quality control without inducing apoptosis.  
Although SIRT1 modification via Tenovin-6 and like drugs has been researched in tumor cells, it has 
yet to be tried in ALS-expressing cells (Ueno, Endo et al. 2014).  However, following transfection of  
HEK293T cells with SOD1G85R DNA, a dose-dependent reduction in mutant SOD aggregates was 
observed.   
The primary goal of  this experiment is to see whether controlled exogenous drug-mediated 
upregulation of  p53 can improve the protein quality control pathway to the extent of  reducing or 
delaying ALS-related phenotype.  Such alterations are to indicated via multiple quantifiable data 
points including weight gain and degeneration over time, two weekly test performance trends, and 
































Figure 1: A: The initial structure of Tenovin-1, a small molecular activator of p53.  Although carrying potential beneficial effects in vitro, it 
is far too water-insoluble in vivo. 
 
B: Tenovin-6 is synthesized via a modification of Tenovin-1 (highlighted in rectangle) which results in a 6 to-7-fold increase in water solubility 





























Figure 2:  A general schematic of the sirtuin-1 pathway and its inhibitory effect via de-acetylation of p53.  Tenovins 1 and 6 return p53 




























Materials and Methods 
 
Cell Culture 
In order to verify the efficacy of  Tenovin-6 in clearing mutant SOD1 aggregates, Human 
Embryonic Kidney 293T cells (HEK293T) were transfected with SOD1G85R DNA to instigate 
protein aggregate formation.  All cells were maintained in a medium composed of: Dulbecco’s 
Modified Eagle Medium (DMEM), 10% Fetal Bovine Serum (FBS), β-Mercaptoethanol, non-
essential amino acids (NEAA), and Glutamax.    
 
Transfection 
HEK293T cells were initially plated in six 60mm petri dishes, each pre-treated with 3mL of  
polyethylenimine (PEI) for thirty minutes.  After the allotted incubation period, PEI and two 
subsequent washes with H2O were aspirated.  The cell concentration for each plate was 4 mL of  1 x 
105 cells/mL in the DMEM mixture.  After a 24-hour incubation period, plates were rinsed and 
aspirated with 2.5mL of  Opti-MEM (OMEM).  A 0.5mL mixture of  OMEM, lipofectamine2000, 
and BOS-SOD1G85R (1.54µg/µL) was then added to the six plates and incubated for five hours, upon 
which 2mL of  DMEM/FBS was added per plate for a 24-hour incubation.  At time of  drug 
addition, six different drug conditions were created in separate 4mL batches.  Plate 1 received 
DMSO alone as a control given that Tenovin-6 was diluted as stock in pure DMSO.  Plates 2-5 
received drug quantities allowing for plate concentrations in increments of  0.4µM up to 2µM.  After 
another 24-hour incubation, all plates underwent a standard lysis protocol utilizing Buffer B, 
Iodoacetamide (IAA), and proteinase inhibitors.  Lysate was then finally fractionated for use in 
western blot.  Protein concentration was measured using a BCA protein concentration assay. 
 





Western blots were run with pre-made 15% polyacrylamide gels each loaded with 40 µg of  sample.  
Primary antibody mix was composed of  9mL of  5% BSA-TBST along with 3µL of  SOD1-100 
(1:3000) Rabbit and 3µL of  β-actin.  Secondary antibody was added for a 1:10000 dilution with anti-
donkey rabbit 800 and anti-donkey mouse 680. 
 
SODG93A Mouse Maintenance 
SOD1G93A males were mated with WT Black-6 females for synthesis of  gender/age/litter matched 
drug trial pairs and stock SOD1G93A positive (SOD+) males for mating purposes.  All SOD1G93A 
negative (SOD-) and unmatched SOD+ females were discarded.  A separate set of  wild-type (WT) 
males and females were designated breeders for WT mating males and both WT and SOD mating 
females.  Five matched WT pairs were also isolated for a drug vehicle control trial to serve as a 
testing and weight baseline.  Except for underweight litters, all mice were split, weaned, tagged, 
tailed, and genotyped upon reaching 21 days of  age.  Upon genotyping and understanding of  
situational requirements, mice were sorted out appropriately.   
 
DNA Extraction 
Upon reaching 21 days of  age, all SOD1 mice were sorted and tagged by gender and litter.  Tails of  
1mm in length were then cut and sampled for genotyping.  For DNA extraction, a Bioline Mytaq 
Extraction Kit was utilized.  Added to each sample were 10mL of  Buffer A, 5mL of  Buffer B, and 
35mL of  water.  Subsequently, each tail-buffer mix was spun at 650rpm for 5 minutes at 75°C and 
then deactivated for 10 minutes at 95°C.  The ensuing mix was then spun at 15000rpm in a 
centrifuge for one minute.  Afterwards, 20µL of  supernatant was transferred to a fresh 1.5mL 




Eppendorf  tube pre-filled with 180µL of  Millipore H2O.  This diluted DNA sample was then kept 
at -20°C for up to three months before being stored at -80°C indefinitely.   
 
PCR 
Upon complete DNA Extraction, samples were prepared for PCR using modifiable count 8-well 
strip individually capped PCR-tubes.  A single reaction mix consisted of  2.25µL of  extracted and 
diluted DNA, 3µL of  MyTaq or GoTaq Polymerase, 0.25µL of  WT primer (Forward and Reverse 
combined), and 0.5µL of  G93A primer (Forward and Reverse combined).  The PCR protocol itself  
was in accordance with Bioline. 
 
DNA Agarose Gel 
Upon PCR completion, a 1.5% agarose gel was molded with the appropriate amount of  wells.  Each 
sample run was accompanied with 1kb ladder along with a negative water control and a positive 
control if  an initial run was unsatisfactory.  Each well was loaded with the full 6µL PCR reaction 
with a running time of  12 minutes at 220V.    
 
Intraperitoneal Injections 
 SOD1G93A mice were administered either drug or vehicle injections via intraperitoneal (IP) 
injections at 33±2 days every five days until ALS-induced fatality approximately 5-6 months later 
(18-20 injections total).  Injection procedure and location were compliant with common research 
techniques and IACUC standards.  No antiseptics were utilized prior to injection and no infections 
or early unforeseen deaths were observed.  Injections were given every five days in contrast to 
weekly testing. This served a dual purpose; increased injection frequency coupled with variable days 




of  injection pre/post testing to eliminate any confound resulting from possible behavioral or 
molecular drug impacts.   
 
Drug Mix 
For low dose tenovin-6 injections of  80µM, 26.4µM, and 8µM, a drug cocktail was utilized in 
accordance with the set precedence of  a previous cancer research paper.  Each drug mix totaled 
100µL (0.1cc) and consisted of: adequate drug quantity for the given dosage, DPBS, 10% DMSO, 
and 20% cyclodextrin.  Drug mixes were made the day of  injection with DPBS and Cyclodextrin 
stored at 4°C and DMSO and Cyclodextrin stored at -20°C.  Insulin needles of  1cc capacity (26 
gauge) were filled and cooled over dry ice until the moment of  injection.  Vehicle control injections 
replaced the removed drug stock with additional DPBS. 
 For the new Tenovin-6 4.5mM trial, a new and simpler protocol was instead adopted 
utilizing necessary drug amounts diluted in DPBS and 10% DMSO only.  Cyclodextrin had been 
dropped from the mix given the favorable water-solubility of  both drugs.  For further efficiency and 
simplicity, pre-mixed injection stocks were formulated and stored at -20°C in aliquots of  1mL for 
future injection needle loading.  Upon each thawing, 10 needles of  0.1cc each were loaded and 
returned to -20°C for easy daily acquisition.  Like the previous protocol, needles were kept over dry 
ice prior to injection.   
 
RotaRod Test Measurement 
RotaRod testing was conducted weekly simultaneously with weight measurements.  A quick single 
round training session was conducted the day prior to testing until proper acclimation to the 
machine was documented.  Protocol was in similar adherence to that supplied by Biotrofix which 
composed of  an initial 1-minute fixed-speed (12 rpm) run followed by a three-trial acceleration test 




every hour.  For texting, the machine was calibrated to begin at a speed of  4 rpm with a five-minute 
acceleration time to a top speed of  12 rpm; protocol was also in accordance with a previous study by 
Bennett et. Al. apart from a speed cap of  12 rpm as opposed to 40 rpm (Bennett, Mead et al. 2014).  
As with all testing, each mouse underwent three separate trials measured in seconds from start to 
fall, which were averaged out at the end of  each testing session.  Unfortunately, early weeks of  
testing generally show greater variance than in later rounds as younger mice are often inclined to 
jump and fall erratically.  Such behaviors were eradicated via early training procedures.  
 
Grip Test Measurement 
Grip strength testing was enacted via a Bioseb grip strength apparatus.  Similar to RotaRod testing, 
measurements were taken weekly, with each trial run averaging three separately recorded 
measurements.  One potential measurement variation of  note was the ability of  mice to not only 
grab the apparatus, but also exert an opposing pulling force as well.  Such actions often registered as 
an above expectation force, yet were considered to indicate their muscular proficiency.  
Measurements were taken on the scale of  25N, and like other recording mediums, all mean scores 
were eventually plotted on a time-lapse graph per subject mouse. 
 
Weighing  
Mice were weighed utilizing a laboratory grade portably electronic balance, which for the later 
4.5mM Tenovin-6 trial was replaced with another balance without ill effect or deviation.  Weekly 
weight measurements were taken to the hundredth of  a gram and were later compiled on a time-
lapse graph.  Measurements were taken on the same day and time that RotaRod testing was carried 
out.   
 





Mouse ALS phenotype was measured using two distinct methods beyond that of  testing results and 
trends.  The first was a self-produced three-stage scale which determined ALS stage based on overall 
appearance and motor deficiencies.  The scale also possessed two early preliminary checkpoints, 
where stage one indicated a general though subtle disturbance to behavior and posture.  Stage two 
indicated slightly more noticeable motor alterations not seen in WT mice at that age.  Stage three 
represented a proper and clearly visible change in motor functionality characterized by shaky 
movement and impeded motor coordination.  At this stage testing scores began to decrease with 
weight following immediately or shortly afterwards.  Stage four was identifiable by severe gait and 
immensely diminished motor skills, with mice often scoring minimally on testing days.  Stage five 
represented end-stage ALS, with subjects displaying nearly complete testing failure and almost full 
muscle paralysis.  Mice at this stage were humanely euthanized days before full motor shutdown and 
death from starvation and dehydration.  
A second a more general phenotype measurement is the leg splay reflex test which can be 
seen in Figure 3.  As ALS progresses, mice, when held upside down by the tail spread their legs 
outwards less and less as motor functionality worsens.  Its 0-3 score scale matched accordingly with 
the first novel 1-5 scale phenotype measurement used.  In this second scale, a 0 score (Fig. 4.0) 
represented normal functionality while a score 1 (Fig. 3.1) indicated a slightly decrease in leg splay 
ability.  Score 2 (Fig. 3.2) marked a significant decrease in muscular integrity while a score of  3 (Fig. 
3.3) was characterized by near complete splay ability of  the legs.   
 
Euthanasia  




Mice were euthanized humanely in accordance with standard IACUC protocols.  Upon reaching 
terminal stages of  ALS at approximately 150-180 days, mice were sacrificed via CO2 chamber and 










































Figure 3: A visual representation of the various phenotypic stages of the 0-3 score hind limb splay test.  As can be seen, progression from 0 
(healthy) to 3 (end-stage) displays a significant decrease in limb stability and integrity.   
 
0: Full limb functionality and muscular integrity 
1: Slight degeneration in muscle and tensile strength 
2: Severely diminished muscle function and splay ability 






















Tenovin-6 Low Dose SODG93A Transgenic Mouse Trial (n=30) 
  
The low dose tenovin-6 mouse trial (n=30) was composed of  three separate dose groups of  80µM, 
26.4µM, and 8µM.  Each group contained 5 pairs of  mice, with each pair gender and litter matched 
with one mouse designated for drug injection and the other for vehicle injection only.  
 
All three low dose Tenovin-6 dosages had no significant effect on age of  death 
 Despite the variance in drug dosages across groups, there was no significant difference in the ages 
of  end-stage death.  Figures 4A-C all display slight differences in mean ages of  death; however once 
all three groups were averaged together, mean ages of  death became nearly identical between drug 
and vehicle groups despite dosage (Fig 4D).  It is important to note that in accordance with IACUC 
humane treatment of  animals, steps were taken to ensure mice did not die due to respiratory failure, 
starvation, or dehydration.  Once mice reached stage 5 end-stage phenotype and were deemed fully 
immobile, they were sacrificed via CO2 and cervical dislocation.     
  
All three low dose Tenovin-6 dosages had no significant effect on phenotype onset 
In addition, experimental drug mice did not differ in onset for progression of  visible ALS 
phenotype when compared to vehicle control mice on both measurement scales.  The maximum 
stage 5 entry age difference between a pair of  trial mice was approximately 10 days while the vast 
majority saw a difference of  no more than three days.  Regardless, any trends or differences proved 
insignificant; where a drug mouse in pair would reach stage 5 a week after the control, a drug mouse 
in another pair would reach stage 5 nearly a week prior to the control.  Oftentimes when any 
discrepancies in phenotype checkpoint ages were seen, they were the result of  noticeable weight 
differences (>2g) already present at birth prior to testing or injections.  While no obvious or 




significant differences were seen, neither were observed any unusual or unexpected phenotypes or 
behaviors.  It was documented on random occasion however, that some mice would reach 
euthanasia requirements only days after reaching stage five, while others could endure for over two 
weeks.  No trend was seen between pairs or groups and seemed to be unpredictable and was thus 







































Figure 4: A+B+C: All three drug groups (n=10 each) consisting of 5 drug/control pairs each were compared to one another based on age 
of death.  While gender was mixed in groups, mice in each pair were both gender and litter matched. Analysis displayed a lack of trend and 
significance at p<.05 in death age.   
 



















Tenovin-6 Baseline Control SOD1 WT  Mouse Trial (n=10) 
  
In addition to the three low dose tenovin-6 group, a fourth WT group was established as a potential 
baseline.  Similar to the preceding drug groups, five properly matched mouse pairs were tested and 
monitored over the same timeframe as drug-group mice.  Experimental mice received vehicle 
control injections while control mice received no injections or modulations to remain as unmodified 
as possible.   
 
Comparing baseline WT and SOD1G93A trials shows no trend disturbances prior to ALS onset 
Given the concern that potentially even vehicle injections could cause unforeseen alterations to 
mouse physiology and genome, the baseline WT trial control group was studied, compared, and 
subjected to the same protocols as the low dose tenovin-6 experimental drug groups.  Testing, 
weighing, and vehicle injections were terminated shortly after the death of  the oldest drug trial 
mouse.  All three tenovin-6 dosage groups exhibited the same weight trends within and between 
pairs, with either a pause or decrease in weight gain approximately beginning at week 10.  Although 
the WT pairs do not display a pause or regression in weight gain due to absence of  the G93A 
transgene, it is worth noting that there is no significant change in weight gain trends induced by 
injections. 
 
Tenovin-6 Baseline Mutant Female SODG93A Transgenic Mouse Trial (n=5) 
  
For further understanding of  baseline SOD1 mutant mouse performance during weekly testing and 
weighing, five individual female SOD1G93A positive mice were placed into a separate testing group.  
All were tested and weighed weekly, but were never injected or contrasted with any litter or gender 




matched mice.  This group was simply utilized as a quick comparison if  in the unlikely event that 
vehicle injections alone served to skew testing/weight/onset data.   
 
Non-injected SOD1G93A trial females exhibit same trends as injected SOD1G93A trial females 
Analysis between the various trial groups displayed no significant differences between drug or 
vehicle control SOD1 positive mice and the non-injected SOD1 positive mice.  Trends in weight 
gain, testing improvements and regression, and visual phenotype checkpoints remained similar 
among all groups.  
 
Tenovin-6 H igh Dose SODG93A Transgenic Mouse Trial (n=10) 
  
Given the indiscernible differences between pairs and groups of  the previous low dose tenovin-6 
trial, a new high dose trial was synthesized utilizing slightly different parameters.  As mentioned 
prior, cyclodextrin was removed from injection mixes given the high water-solubility of  Tenovin-6.  
Unfortunately, at the time of  thesis presentation, this trial had not yet reached end stage.  As such, 
both age of  death and time of  various late-stage phenotype onsets were unable to be quantified and 
compared.  Instead, mid-stage visual phenotype onset was able to be recorded as well as testing and 
weight trends.  An interesting find in the initial low dose tenovin-6 trial was that at approximately 
between the 10th and 12th weeks of  testing, mice reached peak testing performance and weight and 
began to degenerate. This checkpoint was able to be observed before formulation of  this thesis.   
 
Tenovin-6 4.5mM drug mice exhibit early boost in RotaRod scorings 
As evident in Figure 7, both drug and control groups displayed relative uniformity in RotaRod 
testing trends.  Gender imparted no advantage or trial score extension.  Interestingly however, the 




experimental drug group saw a marked increase in performance on week 4 when contrasted with the 
vehicle controls.  This score increase quickly normalized the following week, with testing trends up 
to week 10 remaining similar. Nevertheless, despite the week 4 score increase, the overall trends 
between the two groups did not prove to be significantly different.  A proper follow-up would be to 
observe continued trends to end-stage phenotype and to mark trial performance peaks. 
 
Tenovin-6 4.5mM trial mouse pairs exhibit similar trends in weight progression 
When drug and control groups were compared via mean weight increases over time, no significant 
trend variation was found at p<.05.  While vehicle mice tended to maintain a slight advantage in 
weight as seen in Figure 8, this increase was insignificant, as growth still maintained the same trend 
as in drug mice.   
 
Tenovin-6 4.5mM vehicle control mice exhibit insignificant higher g rip scores than drug 
mice 
At first glance at Figure 9, it was noticed that for the majority of  measured weeks, vehicle control 
mice maintained higher grip test scores than drug mice.  Drug mice did however maintain a 
consistent score trend whereas control mice exhibited a steady decline.  Although the overall trends 
did not prove to be significantly different at p<.05, continued measurements until end stage 















Figure 5:  Mean scores for both the drug and vehicle control groups were plotted on a line graph for trend comparison.  When averaged out, 
both groups maintain similar trends of test scoring apart from week 4.  At this 4.5mM tenovin-6 dosage, drug mice at week 4 displayed a 
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Figure 6: Mean weights between trial pairs were plotted on a line graph for trend comparison. While the vehicle control group does maintain 
a higher weight throughout the experiment, the difference was found to be insignificant (p<.05).  Additionally, both groups had nearly 























1 2 3 4 5 6 7 8 9
Weight ()
Week
Tenovin-6 4.5mM Dose Mean Weight Progression
Drug
Vehicle









Figure 7:  Mean grip test scores were taken and plotted on a line-graph to determine the presence of any trends over 
time.  While score progression proved more erratic compared to RotaRod and weight score trends, it is worth noting the 
generally higher score of the control mice compared to the drug mice for the majority of measure weeks.  Despite this, 
trending depicts drug mice maintaining a lesser but consistent score over 9 weeks whereas vehicle mice exhibit higher 
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Given the effects of  Tenovin-6 in vitro on p53 and protein quality control, the consequent goal was 
to observe if  similar benefits would be seen in vivo.  SOD1G93A transgenic mice, a common animal 
model used to study ALS in vivo seemed to be a good candidate for drug trial. Prior to formulation 
of  each mouse trial group, genotyping was verified and all experimental and control pairs were both 
gender and litter matched.  Tenovin-6 was the first drug to be tested with three separate low dose 
groups, as no clinical dose had yet been established for a mouse model.  The water-insoluble variant 
Tenovin-1 had been previously used by another lab member in the year prior.  However, due to 
unforeseen complications coupled with the significant insolubility of  the drug, it seemed prudent to 
go ahead with a much soluble and effective variant.  Despite the water-solubility of  tenovin-6, initial 
drug trials adhered to a drug mix protocol devised by Ueno et al in 2014 to follow precedent.  
Having utilized tenovin-6 in vivo for cancer research, their mix called for drug diluted in PBS, 10% 
DMSO, and 20% cyclodextrin.  While this protocol was adhered to for the tenovin-6 low dose trials 
as well as the WT baseline trials, they were abandoned for a simpler approach in the high dose 
tenovin-6 trials.   
 Early fears of  tenovin-6 toxicity were partially the cause for such low initial drug dosages, 
given that cancer research utilized the compound to dysregulate autophagy in cancer cells 
(MacCallum, Groves et al. 2013).  Nevertheless, once safe levels were introduced in vitro and 
converted to proper doses in mice, any concerns were alleviated.  The resulting tenovin-6 trial data 
as well did not indicate any abnormal effects stemming from confounding drug effects.  In addition, 
the drug was proven in vitro to clear SOD1G85R aggregates in transfected HEK293T cells.  ‘ 
 The low dose tenovin-6 trial proved to be excellent in terms of  stability and absence of  any 
confounding unforeseen variables.  To further reduce any concerns regarding injection or vehicle 




compound affecting behavior or testing, both a WT baseline group and an untreated SOD positive 
female group were created.  The WT groups satisfactorily indicated that vehicle injections did not 
affect testing performance or weight gain.  The SOD positive female group served as a fundamental 
baseline from which the drug trial groups would expectantly deviate from.  However, given the 
insignificant differences between drug and control mouse score and weight trends, it seemed we may 
have potentially erred too much on the side of  caution.  Consequently, it was decided to significantly 
increase the dosage of  tenovin-6 from the micromolar scale (80µM, 26.4 µM, 8 µM) to a much 
higher millimolar scale (4.5mM).   
 Compared to the low dose drug tenovin-6 groups, the new groups were more simplified in 
terms of  protocol and also yielded a greater yet still subtle variation in results.  To reduce the 
amount of  exogenous substances being introduced, cyclodextrin was removed from drug mixes 
citing the high water-solubility of  both drugs.  Additionally, injection needles were preloaded with 
drug mixes at the time of  first dilution to minimize the amount of  thawing and freezing.   
 Tenovin-6 high (4.5mM) groups unfortunately did not display significant differences in 
trends. However, testing scores and trends did render as more erratic when compared to those of  
the lower dosage tenovins-6 trials. Given these changes, it was decided to begin a new tenovin-6 trial 
with a 13.2mM injection dosage.  This dosage when administered to a 20g mouse registers at 
30mg/kg.  Unfortunately, either due to drug toxicity or user error, all drug mice (n=2) died after 
their first injections.  Tenovin-6 has been noted in several studies to reduce and dysregulate 
autophagy in cancers, thus hinting at potential toxicity at very high doses (MacCallum, Groves et al. 
2013).  Additionally, given the need for proper protein quality control in ALS, a dysfunction in 
autophagy could potentially assist in causing lethality.  Such findings and mechanisms will have to be 
studied further in the future.  




In conclusion, it seems that while tenovins-6 clears protein aggregates in vitro, only very 
high dosage injections of  it in vivo may confer a phenotypic benefit in SOD1G93A mice.  
Furthermore, it seems that given the potential toxic and lethal effects of  tenovins-6 at very high 
doses.  Ages of  phenotypic onset coupled with testing trend analysis must be carefully monitored 
for any significant differences.  As seen in tenovin-6, while higher dose injections may potentially 
improve motor functionality in ALS mice, such high concentrations could have other unforeseen 
mechanistic effects beyond the initial p53 upregulation.  Thus it will be critical in the future to 
harvest and stain tissue appropriately for the correct biomarkers such as autophagy marker 1A/1B-
light chain 3 (LC3) coupled with in-depth testing trend analyses.  LC3 levels would be tested due to 
potential effects of  the Tenovins on autophagy.  If  autophagy were dysregulated due to drug 
administration, levels of  LC3 would be altered indicating disturbed autophagy-related processes 
(Tanida, Ueno et al. 2008).  P53 protein levels would obviously need to be tested as well post-trial via 
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